Company news

Arcturus Therapeutics Holdings Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

June 19, 2024

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

June 6, 2024

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 27, 2024

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 19, 2024

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

May 19, 2024

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

May 7, 2024

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

April 24, 2024

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

March 6, 2024

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

February 25, 2024

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

February 21, 2024

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

February 19, 2024

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

February 4, 2024

PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems

January 4, 2024

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

December 20, 2023

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 3, 2023

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

November 27, 2023

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

November 26, 2023

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

November 26, 2023

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

November 13, 2023

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023

October 24, 2023

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government

October 3, 2023

Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis

September 25, 2023

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

September 18, 2023

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

September 4, 2023

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government

August 13, 2023

Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress

August 6, 2023

Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023

July 23, 2023

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

May 31, 2023

Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress

May 8, 2023

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023

April 25, 2023

Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress

March 27, 2023

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023

March 6, 2023

Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis

January 30, 2023

Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 18, 2022

Arcturus Appoints John Markels, Ph.D. to its Board of Directors

December 12, 2022

Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress

November 8, 2022

Arcturus Therapeutics to Present at the Following Investor Conferences in November

November 6, 2022

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

October 31, 2022

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

October 25, 2022

Arcturus Therapeutics to Attend the Following Investor Conferences

September 26, 2022

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

August 30, 2022

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

August 17, 2022

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

August 8, 2022

Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

July 31, 2022

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2022

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

May 8, 2022

CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

May 4, 2022

Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

April 26, 2022

Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

April 19, 2022

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

March 24, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.